IP Library Granted Patent US 7,022,719
Granted Patent B2
US 7,022,719 · App. 10/418,398 · Granted Apr 4, 2006

Preventing and reversing the formation of advance glycosylation endproducts

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,022,719
App. No.
10/418,398
Granted
Apr 4, 2006
Kind
B2
Abstract

The present invention relates to compositions and methods for inhibiting and reversing nonenzymatic cross-linking (protein aging). Accordingly, compositions are disclosed which comprise an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins, and which additionally reverse pre-formed crosslinks in the advanced glycosylation endproducts by cleaving alpha-dicarbonyl-based protein crosslinks present in the advanced glycosylation endproducts. Certain useful agents are thiazolium salts. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated. A novel immunoassay for detection of the reversal of the nonenzymatic crosslinking is also disclosed.

Claims (5)

1. The compound 3-(2-phenyl-2-oxoethyl)-4,5-dimethylthiazolium chloride.

2. A pharmaceutical composition for administration to an animal comprising a pharmaceutically effective amount of the compound 3-(2-phenyl-2-oxoethyl)-4,5-dimethylthiazolium chloride and a pharmaceutically acceptable carrier therefor.

3. A composition for inhibiting the advanced gylcosylation of a target protein in the oral cavity comprising an effective amount of 3-(2-phenyl-2-oxoethyl)-4,5-dimethylthiazolium chloride and a pharmaceutically acceptable carrier therefor.

4. A composition for topical administration comprising 3-(2-phenyl-2-oxoethyl)-4,5-dimethylthiazolium chloride.

5. A composition for ocular administration comprising 3-(2-phenyl-2-oxoethyl)-4,5-dimethylthiazolium chloride.

Assignments (3)
CHANGE OF NAME Recorded Oct 5, 2007
From: ALTEON, INC.
To: SYNVISTA THERAPEUTICS, INC.
Reel/Frame 019920/0649 →
RELEASE OF SECURITY INTEREST (REEL/FRAME 018746/0676) Recorded Aug 7, 2007
From: BAKER BROS ADVISORS, LLC
To: SYNVISTA THERAPEUTICS, INC.
Reel/Frame 019658/0176 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jan 12, 2007
From: ALTEON INC., A DELAWARE CORPORATION
To: BAKER BROS ADVISORS, LLC, AS COLLATERAL AGENT FOR THE SECURED PARTIES
Reel/Frame 018746/0676 →